
Twist Bioscience Corporation
- Jurisdiction
United States - LEI
549300T23BL59LCOH584 - ISIN
US90184D1000 (TWST )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. Read full profile
Fundamentals
- Net revenue
€309.00M - Gross margin
49.2% - EBIT
-€121.43M - EBIT margin
-39.3% - Net income
-€72.66M - Net margin
-23.5%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
WERNER ROBERT F. | Chief Accounting Officer |
|
|
|
|
Cho Dennis | See Remarks |
|
|
|
|
Finn Patrick John | President and COO |
|
|
|
|
Green Paula | SVP of Human Resources |
|
|
|
|
Laponis Adam | Chief Financial Officer |
|
|
|
|
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Cathie Wood |
|
|
|
Buy |
James Anderson |
|
|
|
Sell |
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 2, 2024 (Q2 2024)